Intro -- Clinical Dilemmas in Inflammatory Bowel Disease -- Contents -- Contributors -- Preface -- Part I: Genes and Phenotype in IBD -- 1 Which will take us further in IBD-study of coding variation or epigenetics? -- 2 IBD in different ethnic groups: same or different? -- Part II: Bugs and IBD-Good, Bad, or Indifferent? -- 3 How does the risk of infection influence management of IBD around the world? -- 4 Traveling with IBD -- 5 What to do about hepatitis B and hepatitis C in patients with IBD -- 6 CMV in IBD-passenger or pathogen? -- 7 Clostridium difficile in IBD: impact, prevention, and treatment -- 8 Prebiotics and synbiotics: panacea or placebo -- 9 Worms: light at the end of their burrow -- 10 Do we really need to vaccinate all patients with IBD? -- Part III: Investigating IBD -- 11 Biomarkers in IBD: myth or marvel? -- 12 Radiation exposure in IBD: how do we minimize the dangers? -- 13 Surveillance colonoscopy in UC: what is the best way to do it? -- Part IV: Medical Therapy -- 5-ASA -- 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward? -- 15 Do 5-ASAs prevent cancer? -- 16 Why do we still use 5-ASAs in Crohn's disease? -- Steroids -- 17 Steroids in Crohn's disease: do the benefits outweigh the dangers? -- Immunomodulators -- 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory? -- 19 Thiopurines and the sun: what should be done? -- 20 Do thiopurines worsen risk and prognosis of cervical neoplasia? -- 21 Optimizing use of methotrexate -- 22 Which calcineurin inhibitor and when? -- Biologics -- 23 Are all anti-TNF agents the same? -- 24 One drug or two: do patients on biologics need concurrent immunomodulation? -- 25 How do we identify patients needing early aggressive therapy and what should we use? -- 26 What is the role of biologics in UC?.

27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy? -- 28 Which extraintestinal manifestations of IBD respond to biologics? -- 29 Use and abuse of biologics in pregnancy -- 30 Is anti-TNF therapy safe to use in people with a history of malignancy? -- 31 The risks of immunomodulators and biologics: what should we tell patients? -- 32 When, how, and in whom should we stop biologics? -- Part V: Other Treatments -- 33 Avoiding drug interactions -- 34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis? -- 35 Stem cell transplantation for Crohn's: will it fulfill its promise? -- 36 Complementary therapy: is there a needle in the haystack? -- Part VI: Surgical Dilemmas in IBD -- 37 Optimizing IBD patients for surgery and recovery -- 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease? -- 39 Laparoscopic or open surgery for IBD? -- 40 Optimizing management of perianal Crohn's disease -- 41 Does anti-TNF therapy increase the risk of complications of surgery? -- 42 Pouches for indeterminate colitis and Crohn's disease: act now, pay later? -- 43 Dealing with pouchitis -- Part VII: Unsolved issues in IBD -- 44 Mucosal healing in IBD: does it matter? -- 45 Vitamin D in IBD: from genetics to bone health via cancer and immunology -- 46 Got milk? Medication use and nursing in women with IBD -- 47 Does stress matter? -- 48 IBS is common in IBD: fact or fallacy? -- 49 So where is all the cancer? -- Part VIII: Nutrition in IBD -- 50 What should patients with IBD eat? -- 51 Enteral nutrition in Crohn's-who for, when, how and which formula? -- 52 Optimizing treatment of iron deficiency anemia -- Part IX: Management Process -- 53 IBD Standards: will they enhance patient care?.

54 Your treatment will not work if the patient does not take it -- 55 Inflammatory bowel disease: what to tell your emergency department (ED) team -- 56 Transitioning from pediatric to adult care -- 57 Medicolegal pitfalls in inflammatory bowel disease care -- Index.

The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.  In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease.  The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking. Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments. This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2018. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.